Time as an Adjunctive Agent to Thrombolytic Therapy

Area of Science:

• Cardiology
• Emergency Medicine
• Public Health

Background:

• Thrombolytic therapy has significantly decreased mortality in acute myocardial infarction (MI).
• Early achievement of infarct-related artery patency is crucial for reducing MI mortality.
• Time to treatment is a critical factor in improving survival rates.

Purpose of the Study:

• To emphasize the importance of time as a critical factor in thrombolytic therapy for acute myocardial infarction (MI).
• To identify and analyze the components contributing to the delay in reperfusion therapy for MI patients.

Main Methods:

• Review of recent clinical trials, including the Thrombolysis in Myocardial Infarction (TIMI) 2 trial.
• Analysis of time delays in reperfusion therapy, categorizing them into patient, transport, door-to-needle, and reperfusion times.
• Quantification of survival benefits associated with earlier treatment initiation.

Main Results:

• Each hour reduction in treatment time can save approximately 10 lives per 1000 patients treated for MI.
• Mortality reduction is directly correlated with the speed of achieving infarct-related artery patency.
• Four key components contribute to the overall delay from MI onset to reperfusion.

Conclusions:

• Time is a critical adjunctive agent in thrombolytic therapy for acute MI.
• Reducing delays in any of the four identified components (patient, transport, door-to-needle, reperfusion) leads to additive survival benefits.
• Optimizing the entire treatment pathway is essential for maximizing patient survival in acute MI.